Breaking Finance News

Zacks Investment Research disclosed Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), upping its target price to $6.00 today

Just yesterday Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) traded 3.63% higher at $5.43. Dicerna Pharmaceuticals Inc’s 50-day moving average is $3.76 and its 200-day moving average is $3.90. The last closing price is up 39.25% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 308,209 shares of DRNA traded hands, up from an average trading volume of 266,212

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) had its target price raised to $6.00 by Zacks Investment Research in a report released 10/04/2016. The new target price indicates a possible upside of 0.10% based on the company's previous closing price.

Recent Performance Chart

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

Dicerna Pharmaceuticals Inc has 52 week low of $2.69 and a 52 week high of $15.93 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 4 brokers have issued a research note on the company. The average stock price target is $14.50 with 3 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *